Results 1 to 10 of about 113,281 (294)
Comparison of Glucose Lowering Efficacy of Human GLP-1 Agonist in Taiwan Type 2 Diabetes Patients after Switching from DPP-4 Inhibitor Use or Non-Use [PDF]
Journal of Personalized Medicine, 2022 To determine the efficacy of glucose control in type 2 diabetes patients who switch from dipeptidyl peptidase-4 (DPP-4) inhibitors use or non-use to GLP-1 receptor agonists (GLP-1 RAs).
Chia-Jen Tsai
exaly +3 more sources
A DPP-4 inhibitor suppresses fibrosis and inflammation on experimental autoimmune myocarditis in mice. [PDF]
PLoS ONE, 2015 Myocarditis is a critical inflammatory disorder which causes life-threatening conditions. No specific or effective treatment has been established. DPP-4 inhibitors have salutary effects not only on type 2 diabetes but also on certain cardiovascular ...
Hiroyuki Hirakawa +7 more
doaj +2 more sources
Clinical Use of DPP-4 Inhibitors [PDF]
Frontiers in Endocrinology, 2019 DPP-4 inhibitors were introduced for the treatment of type 2 diabetes in 2006. They stimulate insulin secretion and inhibit glucagon secretion by elevating endogenous GLP-1 concentrations without an intrinsic hypoglycaemia risk.
Baptist Gallwitz
doaj +3 more sources
Protective effects of DPP-4 inhibitor on podocyte injury in glomerular diseases [PDF]
BMC Nephrology, 2020 Background Dipeptidyl peptidase-4 (DPP-4) is a serine protease that inhibits the degradation of glucagon-like peptide 1. DPP-4 inhibitors are used worldwide to treat type 2 diabetes mellitus and were recently shown to have pleiotropic effects such as ...
Ayano Kubo +6 more
doaj +2 more sources
Renoprotective Effects of DPP-4 Inhibitors [PDF]
Antioxidants, 2021 Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease (ESRD) worldwide. Dipeptidyl peptidase (DPP)-4 inhibitors are widely used in the treatment of patients with type 2 diabetes (T2D). DPP-4 inhibitors reduce glucose levels by inhibiting degradation of incretins.
Daiji Kawanami +4 more
openaire +3 more sources
Urinary exosomal microRNA profiling in type 2 diabetes patients taking dipeptidyl peptidase-4 inhibitor compared with sulfonylurea [PDF]
Kidney Research and Clinical Practice, 2021 Background Dipeptidyl peptidase-4 (DPP-4) inhibitor has been reported to have kidney-protective benefits. To elucidate how antidiabetic agents prevent diabetic kidney disease progression, it is important to investigate their effect on the kidney ...
Nam-Jun Cho +9 more
doaj +1 more source
Kidney & Blood Pressure Research, 2021 Introduction: Dipeptidyl peptidase-4 (DPP-4) has been hypothesized to improve responsiveness to erythropoiesis-stimulating agent (ESA). We aimed to describe the trend in DPP-4 inhibitor prescription patterns and assess the association between DPP-4 ...
Takeshi Hasegawa +7 more
doaj +1 more source
Increasing Age Associated with Higher Dipeptidyl Peptidase-4 Inhibition Rate Is a Predictive Factor for Efficacy of Dipeptidyl Peptidase-4 Inhibitors [PDF]
Diabetes & Metabolism Journal, 2022 Background It is not known which type 2 diabetes mellitus (T2DM) patients would most benefit from dipeptidyl peptidase-4 (DPP-4) inhibitor treatment.
Sangmo Hong +3 more
doaj +1 more source
Frontiers in Public Health, 2021 Introduction: Dipeptidyl peptidase 4 inhibitors (DPP-4 inhibitors) are incretin-based oral antidiabetic drugs. Previous studies have shown an association between increased plasma activity of DPP-4 and chronic hepatitis C virus (HCV) infection. Dipeptidyl
Wei-Hao Hsu +13 more
doaj +1 more source
Frontiers in Endocrinology, 2020 Objective: We recently observed a greater increase in plasma levels of bioactive glucose-dependent insulinotropic polypeptide (GIP) than glucagon-like peptide 1 (GLP-1) using the receptor-mediated bioassays in the subjects with normal glycemic tolerance (
Tsuyoshi Yanagimachi +7 more
doaj +1 more source